Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

linsitinib (ASP7487)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Astellas, Sling Therap

Drug class:

IGF-1R inhibitor

Related drugs:

PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	ASP7487 Sensitive: C3 – Early Trials ASP7487 Sensitive : C3	ASP7487 Sensitive: C3 – Early Trials ASP7487 Sensitive : C3
REST signature	Glioblastoma	REST signature	Glioblastoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
FUS-ERG fusion	Ewing Sarcoma	FUS-ERG fusion	Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
CDKN2A deletion	Ewing Sarcoma	CDKN2A deletion	Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
PAK4 deletion	Ewing Sarcoma	PAK4 deletion	Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ASP7487 + NT-157 Sensitive: D – Preclinical ASP7487 + NT-157 Sensitive : D	ASP7487 + NT-157 Sensitive: D – Preclinical ASP7487 + NT-157 Sensitive : D
TP53 mutation	Breast Cancer	TP53 mutation	Breast Cancer	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D